MedPath

A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)

Completed
Conditions
Rheumatoid Arthritis
Registration Number
NCT00661284
Lead Sponsor
Chugai Pharmaceutical
Brief Summary

A 52-week follow up study to investigate the duration of maintenance of efficacy in patients with RA and achieved low disease activity in clinical trials of MRA and stopped the treatment

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
189
Inclusion Criteria
  • Patients who achieved DAS28 of < 3.2 at the last observation and at least one time point among the two previous assessment time points in a previous studies.
Exclusion Criteria
  • Patients who receive DMARDs or immunosuppressants between the last observation in a previous studies and the first observation in this study

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proportion of patients who maintained efficacy during 52-weeks after the last infusion of MRA in the previous studies.every 4th week up to the 48th week
Relationship between serum IL-6 concentration at the last observation of the previous studies and the duration of maintenance of efficacythroughout study
Secondary Outcome Measures
NameTimeMethod
Efficacy: Proportion of patients who maintained efficacy among patients whose DAS28 was <2.6 at the last observation of the previous studies.throughout study
Efficacy: Time course of DAS28 during the treatment-free period in the present studythroughout study
Efficacy: Relationship between serum IL-6 concentration at the last observation of the previous studies and the time course of DAS28 during the treatment-free period in the present study.throughout study

Trial Locations

Locations (5)

Kanto region

🇯🇵

Kanto, Japan

Kyushu region

🇯🇵

Kyushu, Japan

Chugoku region

🇯🇵

Chugoku, Japan

Sikoku region

🇯🇵

Sikoku, Japan

Tohoku region

🇯🇵

Tohoku, Japan

© Copyright 2025. All Rights Reserved by MedPath